1. Howlader N, Noone AM, Krapcho M, Miller D, Brest A, Yu M, Ruhl J, Tatalovich Z, Mariotto A, Lewis DR, Chen HS, Feuer EJ, Cronin KA, editors. SEER cancer stat facts: non-Hodgkin lymphoma. Bethesda, MD: National Cancer Institute; 2018.
https://seer.cancer.gov/statfacts/html/nhl.html
2. Jacobson CA, Longo DL. Non-Hodgkin’s lymphoma. New York, NY: McGraw-Hill Education; 2018.
3. World Health Organization classification of tumours;E Campo,2008
4. Savage KJ, Zeynalova S, Kansara RR. Validation of a prognostic model to assess the risk of CNS disease in patients with aggressive B-cell lymphoma. Blood. 2014;124(21):394.
5. Vitolo U, Chiappella A, Ferreri AJ, Martelli M, Baldi I, Balzarotti M, et al. First-line treatment for primary testicular diffuse large B-cell lymphoma with rituximab-CHOP, CNS prophylaxis, and contralateral testis irradiation: final results of an international phase II trial. J Clin Oncol. 2011;29(20):2766–72.